Works about LIRAGLUTIDE

Results: 400
    1
    2

    Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study).

    Published in:
    Metabolites (2218-1989), 2025, v. 15, n. 6, p. 398, doi. 10.3390/metabo15060398
    By:
    • Al-Najim, Werd;
    • Dehestani, Babak;
    • Al-Humadi, Ahmed W.;
    • Bodicoat, Danielle H.;
    • Papamargaritis, Dimitris;
    • Lean, Michael;
    • McGowan, Barbara;
    • Webb, David R.;
    • Wilding, John PH;
    • Davies, Melanie J.;
    • le Roux, Carel W.
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double‐blind, placebo‐controlled trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 4905, doi. 10.1111/dom.15889
    By:
    • Dejgaard, Thomas F.;
    • Frandsen, Christian S.;
    • Kielgast, Urd;
    • Størling, Joachim;
    • Overgaard, Anne J.;
    • Svane, Maria S.;
    • Olsen, Markus Harboe;
    • Thorsteinsson, Birger;
    • Andersen, Henrik U.;
    • Krarup, Thure;
    • Holst, Jens J.;
    • Madsbad, Sten
    Publication type:
    Article
    20
    21
    22
    23

    Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 1, p. 201, doi. 10.1111/dom.15306
    By:
    • Foghsgaard, Signe;
    • Vedtofte, Louise;
    • Andersen, Emilie S.;
    • Bahne, Emilie;
    • Andreasen, Camilla;
    • Sørensen, Anne L.;
    • Forman, Julie L.;
    • Mathiesen, Elisabeth R.;
    • Svare, Jens A.;
    • Clausen, Tine D.;
    • Damm, Peter;
    • Holst, Jens J.;
    • Knop, Filip K.;
    • Vilsbøll, Tina
    Publication type:
    Article
    24

    The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3465, doi. 10.1111/dom.15244
    By:
    • Giorgino, Francesco;
    • Guerci, Bruno;
    • Füchtenbusch, Martin;
    • Lebrec, Jérémie;
    • Boye, Kristina;
    • Orsini Federici, Marco;
    • Heitmann, Elke;
    • Dib, Anne;
    • Yu, Maria;
    • Sapin, Hélène;
    • García‐Pérez, Luis‐Emilio
    Publication type:
    Article
    25

    The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient‐reported outcomes at 24 months.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3453, doi. 10.1111/dom.15145
    By:
    • Boye, Kristina S.;
    • Lebrec, Jérémie;
    • Dib, Anne;
    • Heitmann, Elke;
    • Federici, Marco Orsini;
    • Yu, Maria;
    • Sapin, Hélène;
    • Barrett, Annabel;
    • Guerci, Bruno;
    • Giorgino, Francesco;
    • Füchtenbusch, Martin;
    • García‐Pérez, Luis‐Emilio
    Publication type:
    Article
    26

    Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1632, doi. 10.1111/dom.15017
    By:
    • Nerild, Henriette H.;
    • Brønden, Andreas;
    • Gether, Ida M.;
    • Hellmann, Pernille H.;
    • Baekdal, Mille;
    • Gillum, Matthew P.;
    • Svenningsen, Jens S.;
    • Hartmann, Bolette;
    • Rathor, Naveen;
    • Kudiyanur Muniraju, Hanna Angelene;
    • Rehfeld, Jens F.;
    • Holst, Jens J.;
    • Vilsbøll, Tina;
    • Sonne, David P.;
    • Knop, Filip K.
    Publication type:
    Article
    27
    28
    29
    30
    31

    T he R eal‐World O bservational P rospective Study of H ealth Outcomes with Dulaglut i de and Liraglutide in Patients with Typ e 2 Diabete s (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2373, doi. 10.1111/dom.14823
    By:
    • Guerci, Bruno;
    • Giorgino, Francesco;
    • Sapin, Hélène;
    • Boye, Kristina;
    • Lebrec, Jérémie;
    • Federici, Marco Orsini;
    • Heitmann, Elke;
    • Dib, Anne;
    • Füchtenbusch, Martin;
    • García‐Pérez, Luis‐Emilio
    Publication type:
    Article
    32
    33
    34
    35

    Improving beta‐cell secretory function and glycaemia in young‐onset type 2 diabetes: A pilot, 12‐month, randomized trial of a novel, continuous glucose monitor‐guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 4, p. 747, doi. 10.1111/dom.14621
    By:
    • Middleton, Timothy L.;
    • Constantino, Maria I.;
    • McGill, Margaret;
    • D'Souza, Mario;
    • Yue, Dennis K.;
    • Twigg, Stephen M.;
    • Wu, Ted;
    • Wong, Jencia
    Publication type:
    Article
    36
    37
    38

    Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA‐PRIME).

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 204, doi. 10.1111/dom.14566
    By:
    • Unger, Jeff;
    • Allison, Dale C.;
    • Kaltoft, Margit;
    • Lakkole, Kavitha;
    • Panda, Jayant K.;
    • Ramesh, Chethana;
    • Sargin, Mehmet;
    • Smolyarchuk, Elena;
    • Twine, Melissa;
    • Wolthers, Benjamin;
    • Yarimbas, Gizem;
    • Zoghbi, Marouan
    Publication type:
    Article
    39
    40
    41
    42
    43

    Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1351, doi. 10.1111/dom.14347
    By:
    • Pasquel, Francisco J.;
    • Urrutia, Maria A.;
    • Cardona, Saumeth;
    • Coronado, Karla W. Z.;
    • Albury, Bonnie;
    • Perez‐Guzman, Mireya C.;
    • Galindo, Rodolfo J.;
    • Chaudhuri, Ajay;
    • Iacobellis, Gianluca;
    • Palacios, Juan;
    • Farias, Javier M.;
    • Gomez, Patricia;
    • Anzola, Isabel;
    • Vellanki, Priyathama;
    • Fayfman, Maya;
    • Davis, Georgia M.;
    • Migdal, Alexandra L.;
    • Peng, Limin;
    • Umpierrez, Guillermo E.
    Publication type:
    Article
    44

    Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1409, doi. 10.1111/dom.14343
    By:
    • Ahmad, Ehtasham;
    • Waller, Helen L.;
    • Sargeant, Jack A.;
    • Webb, M'Balu A.;
    • Htike, Zin Zin;
    • McCann, Gerry P.;
    • Gulsin, Gaurav;
    • Khunti, Kamlesh;
    • Yates, Tom;
    • Henson, Joseph;
    • Davies, Melanie J.;
    • Webb, David R.
    Publication type:
    Article
    45

    The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double‐blind, placebo‐controlled trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1262, doi. 10.1111/dom.14334
    By:
    • Whicher, Clare A.;
    • Price, Hermione C.;
    • Phiri, Peter;
    • Rathod, Shanaya;
    • Barnard‐Kelly, Katharine;
    • Ngianga, Kandala;
    • Thorne, Kerensa;
    • Asher, Carolyn;
    • Peveler, Robert C.;
    • McCarthy, Joanne;
    • Holt, Richard I. G.
    Publication type:
    Article
    46
    47
    48

    Corrigendum.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 296, doi. 10.1111/dom.14249
    Publication type:
    Article
    49
    50

    Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2487, doi. 10.1111/dom.14160
    By:
    • Verma, Subodh;
    • McGuire, Darren K.;
    • Bain, Stephen C.;
    • Bhatt, Deepak L.;
    • Leiter, Lawrence A.;
    • Mazer, C. David;
    • Monk Fries, Tea;
    • Pratley, Richard E.;
    • Rasmussen, Søren;
    • Vrazic, Hrvoje;
    • Zinman, Bernard;
    • Buse, John B.
    Publication type:
    Article